评估生物仿制药的价值:管理护理组织的成本效益方法
Vishwanauth Persaud1, Reanne Bernstein1, Albert Wertheimer1
1Department of Social, Behavioral and Administrative Sciences, Touro College of Pharmacy, New York, NY, USA.
Journal of pharmacy practice
|November 3, 2025
概括
生物类似药提供了同等或更好的临床结果,并降低了慢性疾病如RA,CD和T1DM的成本. 然而,由于折扣激励和提供商的犹,不一致的表单配置阻碍了它们的采用.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 相对有效性研究研究比较
背景情况:
- 生物药物对于慢性疾病管理至关重要,但成本昂贵.
- 生物类药物提供了负担得起的替代品,在安全性和有效性方面与参考生物药物具有很高的相似性.
- 管理护理组织 (MCO) 通过表单管理影响生物类似物采用.
研究的目的:
- 评估与参考生物制剂相比,生物类似药在风湿性关节炎 (RA),克罗恩病 (CD) 和1型糖尿病 (DM) 中的成本效益.
- 分析定价差异,并确定MCO配方产品中生物类药物吸收的障碍.
- 为MCO和决策者提供信息,以优化制剂决策,以控制成本和患者获取.
主要方法:
- 使用增量成本效益比率 (ICER) 的比较性成本效益分析.
- 生物生物相似对的评估:阿达利穆马布 (Cyltezo) 与胡米拉,因弗利西穆马布 (Avsola) 与雷米卡德,以及胰岛素格拉 (Semglee) 与兰图斯.
- 对临床试验数据,现实世界的证据和在MCOs中的表单配置进行审查.
主要成果:
- 生物类药物表现出优越的成本效益,Cyltezo和Avsola显示出比它们的参考生物药物更好的有效性和更低的成本.
- 塞姆格利以显著降低成本提供了与兰图斯相当的结果,支持成本最小化战略.
- 尽管具有有利的临床和经济特征,但由于折扣合同和供应商的犹,生物类药物面临着不一致的配方布局.
结论:
- 生物仿制药可为RA,CD和T1DM提供显著的成本节约和可比或改善的临床结果.
- 解决折扣驱动的激励措施,提高透明度和改善提供者教育对于增加生物类似药的采用至关重要.
- 将表单实践与临床证据相协调对于可持续的医疗保健资源分配和改善患者获取至关重要.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
223
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
223
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
395
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
395
Bioequivalence: Overview
1.8K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.8K
Bioequivalence studies: Biowaivers
214
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
214
Bioequivalence of Drugs: Drugs with Multiple Indications
145
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
145
Methods of Documentation VI: Case Management Model
847
The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic...
For example, a patient with a chronic...
847


